Viridian Therapeutics/$VRDN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Ticker
$VRDN
Sector
Primary listing
Employees
143
Headquarters
Website
VRDN Metrics
BasicAdvanced
$1.9B
-
-$3.56
0.48
-
Price and volume
Market cap
$1.9B
Beta
0.48
52-week high
$25.21
52-week low
$9.90
Average daily volume
1.2M
Financial strength
Current ratio
11.006
Quick ratio
10.713
Long term debt to equity
2.736
Total debt to equity
4.48
Interest coverage (TTM)
-125.45%
Profitability
EBITDA (TTM)
-371.102
Gross margin (TTM)
-99,761.97%
Net profit margin (TTM)
-112,806.89%
Operating margin (TTM)
-121,831.15%
Management effectiveness
Return on assets (TTM)
-39.77%
Return on equity (TTM)
-65.88%
Valuation
Price to revenue (TTM)
5,879.218
Price to book
5.8
Price to tangible book (TTM)
5.8
Price to free cash flow (TTM)
-5.791
Free cash flow yield (TTM)
-17.27%
Free cash flow per share (TTM)
-4.001
Growth
Revenue change (TTM)
5.90%
Earnings per share change (TTM)
41.77%
3-year revenue growth (CAGR)
-30.13%
3-year earnings per share growth (CAGR)
-7.54%
What the Analysts think about VRDN
Analyst ratings (Buy, Hold, Sell) for Viridian Therapeutics stock.
Bulls say / Bears say
FDA granted Breakthrough Therapy Designation to veligrotug on May 7, 2025, potentially qualifying the drug for Priority Review and speeding its path to market if approved (Business Wire)
Viridian reported a cash, cash equivalents, and short-term investments balance of $563.4 million as of June 30, 2025, providing funding runway into the second half of 2027 and supporting development through launch (TradingView )
Entered an exclusive collaboration and license agreement with Kissei Pharmaceutical on July 30, 2025, securing a $70 million upfront payment and up to $315 million in milestones plus tiered royalties, strengthening non-dilutive funding and validating its TED programs (SEC Form 8-K)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
VRDN Financial Performance
Revenues and expenses
VRDN Earnings Performance
Company profitability
VRDN News
AllArticlesVideos
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
Business Wire1 week ago
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
Business Wire1 week ago
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viridian Therapeutics stock?
Viridian Therapeutics (VRDN) has a market cap of $1.9B as of October 29, 2025.
What is the P/E ratio for Viridian Therapeutics stock?
The price to earnings (P/E) ratio for Viridian Therapeutics (VRDN) stock is 0 as of October 29, 2025.
Does Viridian Therapeutics stock pay dividends?
No, Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders as of October 29, 2025.
When is the next Viridian Therapeutics dividend payment date?
Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders.
What is the beta indicator for Viridian Therapeutics?
Viridian Therapeutics (VRDN) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.